| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1025: Ublituximab for treating relapsing multiple sclerosis |
|
Medicine details |
|
| Medicine name | ublituximab (Briumvi®) |
| Formulation | 150 mg concentrate for solution for infusion |
| Reference number | 4273 |
| Indication | For treating relapsing multiple sclerosis |
| Company | Neuraxpharm UK Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 12/11/2024 |
| NICE guidance | TA1025: Ublituximab for treating relapsing multiple sclerosis |